Significant Ownership of Slate Path Capital LP
- Signature - Title
- /s/ Thomas Hansen - By: Jades GP, LLC, General Partner, By: Thomas Hansen, Chief Financial Officer and Chief Operating Officer
- Location
- New York, NY
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Slate Path Capital LP.
Follow Filing Activity
Follow Slate Path Capital LP and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of Slate Path Capital LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| TVRD | Tvardi Therapeutics, Inc. | Common stock, par value $0.001 per share | 7.5% | $19,257,627 | 704,118 | Slate Path Capital LP | 30 Jun 2025 | ||
| RKT | Rocket Companies, Inc. | Class A common stock, par value $0.00001 per share | 2% | $375,158,040 | 19,358,000 | Slate Path Capital LP | 30 Sep 2025 | ||
| CUE | Cue Biopharma, Inc. | Common stock, par value $0.001 per share | 1.4% | $790,199 | 918,836 | Slate Path Capital LP | 31 Dec 2024 | ||
| CYCN | Cyclerion Therapeutics, Inc. | Common Stock, no par value | 0% | $0 | 0 | Slate Path Capital LP | 30 Nov 2024 |
Schedules 13D/G Reported by Slate Path Capital LP:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.